4/A: Verrica Pharmaceuticals Executive Corrects Stock Award Reporting After VP-102 Commercial Sale
SEC Filing (Form 4/A)
Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, amends a previous SEC Form 4 filing to accurately reflect the number of restricted stock units (RSUs) awarded following the first commercial sale of VP-102.
Summary
- Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, filed an amended SEC Form 4 to correct the number of restricted stock units (RSUs) awarded.
- The original filing on August 28, 2023, incorrectly reported the number of RSUs.
- The correction reflects the full size of the RSU award, not just the portion that vested on August 24, 2023, upon the first commercial sale of VP-102.
- The corrected filing shows Hayes beneficially owns 231,925 shares of common stock.
Sentiment
Score: 6
Explanation: The document is a routine correction of a previous filing. It doesn't contain any particularly positive or negative information about the company's overall prospects.
Negatives
- The initial Form 4 filing contained an error in reporting the number of RSUs awarded.
Future Outlook
The remaining 50% of the RSUs will vest on August 24, 2024, the one-year anniversary of the first commercial sale of VP-102.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The correction of the RSU award reporting ensures transparency for shareholders regarding executive compensation.
Key Dates
| Date | Description |
|---|---|
| 08/24/2023 | Date of earliest transaction and first commercial sale of VP-102, triggering vesting of 50% of RSUs. |
| 08/28/2023 | Date of original Form 4 filing which contained an error. |
| 02/06/2025 | Date of signature on the amended form. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.